Inflammation drives alternative first exon usage to regulate immune genes including a novel iron regulated isoform of Aim2

Abstract

Determining the layers of gene regulation within the innate immune response is critical to our understanding of the cellular responses to infection and dysregulation in disease. We identified a conserved mechanism of gene regulation in human and mouse via changes in alternative first exon (AFE) usage following inflammation, resulting in changes to isoform usage. Of these AFE events, we identified 50 unannotated transcription start sites (TSS) in mice using Oxford Nanopore native RNA sequencing, one of which is the cytosolic receptor for dsDNA and known inflammatory inducible gene, Aim2. We show that this unannotated AFE isoform of Aim2 is the predominant isoform transcribed during inflammation and contains an iron-responsive element in its 5′UTR enabling mRNA translation to be regulated by iron levels. This work highlights the importance of examining alternative isoform changes and translational regulation in the innate immune response and uncovers novel regulatory mechanisms of Aim2.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE141754.

The following previously published data sets were used

Article and author information

Author details

  1. Elektra Kantzari Robinson

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  2. Pratibha Jagannatha

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0257-3139
  3. Sergio Covarrubias

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  4. Matthew Cattle

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  5. Valeriya Smaliy

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  6. Rojin Safavi

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  7. Barbara Shapleigh

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  8. Robin Abu-Shumays

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  9. Miten Jain

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    No competing interests declared.
  10. Suzanne M Cloonan

    Division of Pulmonary and Critical Care Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, United States
    Competing interests
    No competing interests declared.
  11. Mark Akeson

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    Competing interests
    Mark Akeson, holds options in Oxford Nanopore Technologies (ONT). MA is a paid consultant to ONT received reimbursement for travel, accommodation and conference fees to speak at events organized by ONT. MA is an inventor on 11 UC patents licensed to ONT (6,267,872, 6,465,193, 6,746,594, 6,936,433, 7,060,50, 8,500,982, 8,679,747, 9,481,908, 9,797,013, 10,059,988, and 10,081,835). MA received research funding from ONT..
  12. Angela N Brooks

    Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, United States
    For correspondence
    anbrooks@ucsc.edu
    Competing interests
    Angela N Brooks, received reimbursement for travel, accommodation and conference fees to speak at events organized by Oxford Nanopore Technologies (ONT)..
  13. Susan Carpenter

    Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, United States
    For correspondence
    sucarpen@ucsc.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1427-3897

Funding

NIH Office of the Director (HG010053)

  • Angela N Brooks

Oxford Nanopore Technologies (SC20130149)

  • Mark Akeson

UCSC Committee on Research (COR)

  • Susan Carpenter

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal work was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee at the University of California Santa Cruz (Protocol number CARPS1810).

Copyright

© 2021, Robinson et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,977
    views
  • 437
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Elektra Kantzari Robinson
  2. Pratibha Jagannatha
  3. Sergio Covarrubias
  4. Matthew Cattle
  5. Valeriya Smaliy
  6. Rojin Safavi
  7. Barbara Shapleigh
  8. Robin Abu-Shumays
  9. Miten Jain
  10. Suzanne M Cloonan
  11. Mark Akeson
  12. Angela N Brooks
  13. Susan Carpenter
(2021)
Inflammation drives alternative first exon usage to regulate immune genes including a novel iron regulated isoform of Aim2
eLife 10:e69431.
https://doi.org/10.7554/eLife.69431

Share this article

https://doi.org/10.7554/eLife.69431

Further reading

    1. Developmental Biology
    2. Genetics and Genomics
    Anne-Sophie Pepin, Patrycja A Jazwiec ... Sarah Kimmins
    Research Article Updated

    Paternal obesity has been implicated in adult-onset metabolic disease in offspring. However, the molecular mechanisms driving these paternal effects and the developmental processes involved remain poorly understood. One underexplored possibility is the role of paternally induced effects on placenta development and function. To address this, we investigated paternal high-fat diet-induced obesity in relation to sperm histone H3 lysine 4 tri-methylation signatures, the placenta transcriptome, and cellular composition. C57BL6/J male mice were fed either a control or high-fat diet for 10 weeks beginning at 6 weeks of age. Males were timed-mated with control-fed C57BL6/J females to generate pregnancies, followed by collection of sperm, and placentas at embryonic day (E)14.5. Chromatin immunoprecipitation targeting histone H3 lysine 4 tri-methylation (H3K4me3) followed by sequencing (ChIP-seq) was performed on sperm to define obesity-associated changes in enrichment. Paternal obesity corresponded with altered sperm H3K4me3 at promoters of genes involved in metabolism and development. Notably, altered sperm H3K4me3 was also localized at placental enhancers. Bulk RNA-sequencing on placentas revealed paternal obesity-associated sex-specific changes in expression of genes involved in hypoxic processes such as angiogenesis, nutrient transport, and imprinted genes, with a subset of de-regulated genes showing changes in H3K4me3 in sperm at corresponding promoters. Paternal obesity was also linked to impaired placenta development; specifically, a deconvolution analysis revealed altered trophoblast cell lineage specification. These findings implicate paternal obesity effects on placenta development and function as one potential developmental route to offspring metabolic disease.

    1. Genetics and Genomics
    Thomas J O'Brien, Ida L Barlow ... André EX Brown
    Research Article

    There are thousands of Mendelian diseases with more being discovered weekly and the majority have no approved treatments. To address this need, we require scalable approaches that are relatively inexpensive compared to traditional drug development. In the absence of a validated drug target, phenotypic screening in model organisms provides a route for identifying candidate treatments. Success requires a screenable phenotype. However, the right phenotype and assay may not be obvious for pleiotropic neuromuscular disorders. Here, we show that high-throughput imaging and quantitative phenotyping can be conducted systematically on a panel of C. elegans disease model strains. We used CRISPR genome-editing to create 25 worm models of human Mendelian diseases and phenotyped them using a single standardised assay. All but two strains were significantly different from wild-type controls in at least one feature. The observed phenotypes were diverse, but mutations of genes predicted to have related functions led to similar behavioural differences in worms. As a proof-of-concept, we performed a drug repurposing screen of an FDA-approved compound library, and identified two compounds that rescued the behavioural phenotype of a model of UNC80 deficiency. Our results show that a single assay to measure multiple phenotypes can be applied systematically to diverse Mendelian disease models. The relatively short time and low cost associated with creating and phenotyping multiple strains suggest that high-throughput worm tracking could provide a scalable approach to drug repurposing commensurate with the number of Mendelian diseases.